**18F-FDG PET-CT incidental lung findings in asymptomatic COVID-19 patients: evidences from the Italian core of the first pandemic peak**

Bonanomi Alice¹,²*, Bonaffini Pietro Andrea¹,², Spallino Marianna³, Dulcetta Ludovico¹,², Franco Paolo Niccolò¹,², Valle Clarissa¹,², Marra Paolo¹,², Bruno Andrea³, Sironi Sandro¹,²

¹Department of Radiology, Papa Giovanni XXIII Hospital, Bergamo, Italy
²School of Medicine, University of Milano Bicocca, Milano, Italy
³Department of Nuclear Medicine, Papa Giovanni XXIII Hospital, Bergamo, Italy

**A B S T R A C T**

**Objective(s):** To illustrate incidental ¹⁸F-FDG PET-CT findings and related CT alterations of suspicious pulmonary interstitial involvement in asymptomatic oncologic patients during the first COVID-19 outbreak in the core of Italian peak.

**Methods:** We retrospectively evaluated the ¹⁸F-FDG PET-CT follow-up examinations performed during the first Italian COVID-19 outbreak (March 3rd-April 15th, 2020) in 10 asymptomatic oncologic patients with a highly suspicious interstitial pulmonary involvement on CT. Six cases were confirmed SARS-CoV-2 by molecular tests. The following parameters were assessed: 1] lung involvement on co-registration CT as extension (laterality, number of lobes), pattern (ground-glass opacities/GGO, consolidations, mixed) and stage (early, progressive, peak, and absorption); 2] the maximum standardized uptake value (SUVₘₐₓ) of lung lesions on ¹⁸F-FDG PET.

**Results:** The involved lobes were 5 in 5 cases (3 confirmed SARS-CoV-2), 2-4 in 4 cases and 1 in 1 case. GGO were found in all patients; 3 cases also showed a combination of GGO and peripheral consolidations (mixed). Five cases were suggestive for an early stage of interstitial pneumonia, 4 for progressive and 1 for peak. All the lung lesions showed increased FDG uptake. In early stages SUVₘₐₓ ranged from 1.5 to 11, in progressive from 3.3 to 6.8, in peak from 2.4 to 7.7. SUVₘₐₓ ranged 1.5-11 in patients with only GGO and 2.8-7.7 in those with mixed pattern.

**Conclusions:** ¹⁸F-FDG PET-CT findings in suspected COVID-19 pulmonary involvement of asymptomatic oncologic patients showed an increase in FDG uptake of GGO and consolidations, but with a wide and apparently nonspecific range of SUVₘₐₓ values.

---

**Introduction**

Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) infection, mainly affects the respiratory system, leading to several flu-like symptoms (weakness, cough and fever).

In more severe cases, COVID-19 evolves in bilateral interstitial pneumonia, which can precipitate in acute respiratory distress syndrome (ARDS). However, in many cases COVID-19 patients can be completely asymptomatic. According to the literature, the prevalence of asymptomatic cases has been described as a large part of all COVID-19 infections, ranging from 30.8% to 73% (1, 2). Consequently, it is expected that undocumented and asymptomatic patients could represent an

---

*Corresponding author:* Alice Bonanomi. Department of Radiology, ASST Papa Giovanni XXIII, Piazza OMS 1, 24127 Bergamo (BG), Italy. Tel: 0352675030; E-mail address: a.bonanomi10@campus.unimib.it

© 2022 mums.ac.ir All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
important source for SARS-CoV-2 spread (3).

Computed tomography (CT) represents the imaging mainstay in the assessment of lung involvement in COVID-19 patients, being able to accurately depict the extent of disease and its evolution. CT also demonstrated higher sensitivity, compared to chest X-ray (CXR), in the detection of early lung disease stages, even in asymptomatic patients. Particularly, it has been described that more than 50% of asymptomatic infected patients show lung abnormalities on CT investigations, especially ground glass opacities (GGO)(2).

Fluorine 18 fluorodeoxyglucose (18F-FDG) PET-CT is known to identify, beside neoplastic processes, inflammatory and infective tissues, due to their increased glycolytic metabolism. Therefore, not surprisingly 18F-FDG PET-CT can demonstrate increased metabolic activity also in cases of interstitial pneumonia, although it does not play a specific role per se in COVID-19 imaging workup (4-6). Furthermore, as functional imaging techniques, nuclear medicine studies could theoretically identify metabolic active sites of inflammation in the early stages (7,8).

On these bases, the aim of this study is to describe the main incidental 18F-FDG PET-CT findings and related CT alterations of suspicious pulmonary interstitial involvement in asymptomatic oncologic patients during the first COVID-19 outbreak in the core of Italian peak.

METHODS

Study population

We retrospectively enrolled all patients with the following inclusion criteria: a) 18F-FDG PET-CT examinations performed for oncologic follow-up purposes during the first Italian COVID-19 outbreak (March 3rd-April 15th, 2020); b) incidental detection of highly suspicious SARS-CoV-2 related pulmonary involvement, not ascribable to the underlying neoplastic pathology on co-registration CT; c) completely asymptomatic patients at the time of PET-CT scans (except for one patient who referred an episode of fever 37.5°C, the days before the exam).

Patients’ medical history and outcome were retrospectively retrieved from electronic medical records (Table 1). Particularly, results of real-time reverse polymerase chain reaction (RT-PCR) from pharyngeal swabs and/or antibodies from serological analysis were assessed. If not available, patients were considered in the analysis, whenever presenting at CT a pattern of pulmonary involvement highly suspicious for interstitial pneumonia (also considering the epidemiological contingency) (9). For those patients who performed further imaging studies during follow up, they were also retrospectively reviewed from the picture archiving and communication system.

Table 1. Demographic characteristics of included patients. # all PET were performed for follow-up

| # Patient | Sex | Age | PET-CT Indication | Suggestive CT (lung) | Primary tumor Uptake | Distant tumor Uptake | SARS-CoV-2 diagnosis |
|-----------|-----|-----|-------------------|----------------------|----------------------|---------------------|----------------------|
| 001       | F   | 57  | Nasopharynx cancer| None                 | None                 | None                | Positive quantitative serological test |
| 002       | M   | 71  | Hepatocarcinoma   | None                 | None                 | Pulmonary module    | Suggestive CT (lung)      |
| 003       | M   | 57  | Oropharynx cancer | None                 | Yes                  | None                | Positive quantitative serological test |
| 004       | M   | 69  | Melanoma          | None                 | Yes                  | Axillary node       | Suggestive CT (lung)      |
| 005       | F   | 50  | Breast cancer     | None                 | Yes                  | Axillary node       | Suggestive CT (lung)      |
| 006       | F   | 71  | Breast cancer     | None                 | Yes                  | None                | Positive nasal swab (PCR) |
| 007       | M   | 72  | Duodenal cancer   | None                 | Yes                  | None                | Positive nasal swab (PCR) |
| 008       | F   | 77  | Adnexal cancer    | Fever the day before | Yes                  | None                | Positive nasal swab (PCR) |
| 009       | F   | 81  | Urothelial cancer | None                 | Yes                  | None                | Suggestive CT (lung)      |
| 010       | M   | 69  | Lymphoma          | None                 | No                   | None                | Positive nasal swab (PCR) |

18F-FDG PET-CT and CT imaging: Scanning protocol

According to EANM guidelines (10) 18F-FDG PET-CT was performed after >4 hours fasting and with blood glucose level <200 mg/dL. We administered an intravenously dose of 3.7 MBq/kg and performed imaging 55-75 min post glucose injection. Total-body PET images were acquired in 3D with Flow Motion technique (Biograph mCT Flow S64 4R, Siemens) at a...
speed of 1.1 mm/sec (200×200 matrix) corresponding to a stop and go acquisition of 2.00 min per bed. Low dose CT was recorded for the correction of attenuation and anatomical localization, with the following parameters: 120 kV, CARE Dose4D (performs automatic tube current modulation in the angular and longitudinal directions and also adapts to different anatomical regions and patient sizes), 0.5 sec per rotation, delay 2 sec, pitch 1.5, layer thickness 3 mm, 512×512 matrix and a pixel reconstruction of 0.98 mm.

Before PET completion, total body CT scans were acquired in the same session, with patient supine, 100 kV and automated tube current modulation. Collimation, pitch and rotation time were 16×1.2 mm, 1.1:1 and 0.5 sec, respectively. Slice thickness was 2.0 mm. All CT studies were performed unenhanced. Moreover, 4 patients additionally underwent contrast enhanced CT (CECT) studies: 2 patients 30 days after the pneumonia evidence and 2 one week before the PET-CT. All the 4 CECT scans were performed as standard oncologic follow-up, on a 64-detector CT scanner (Brilliance, Philips) during the intravenous bolus injection of 1.3-1.5 mL/kg of non-ionic contrast medium (iomeprol 350 mg/mL; Bracco Imaging), at flow rate of 2.5-3.5 mL/s and followed by a rapid saline solution flush (30-40 mL, flow rate 3 mL/s). Images were acquired in a single portal venous phase, about 80-90 seconds after contrast injection.

**Images analysis**

Image analysis for CT was performed independently by two radiologists, with 3 years of experience in CT imaging (A.B. and P.N.F.). Unenhanced co-registration CT of PET scans was used for lung assessment and the following characteristics were recorded: a) extension of lung involvement, in terms of laterality (unilateral/bilateral) and number of involved lobes (from 1 to 5); b) pattern, as GGO, consolidations or mixed (both GGO and consolidations); c) stage, which included early, progressive, peak and absorption, as described by Feng P et al (11). In the mentioned study, stages are defined from the day of onset of symptoms. Being our patients asymptomatic, in this study stages were assigned according to morphologic appearance of lung alterations on CT. Namely, early stage (stage 1) is characterized by GGO, mostly subpleural at lower lobes. In the progressive stage (stage 2) there is a bilateral extension of the pneumonia, with diffuse GGO, crazy paving pattern and initial consolidations. The peak stage (stage 3) is characterized by prevalent parenchymal consolidations with residual parenchymal bands and occasionally GGO. The absorption stage (stage 4) represents a gradual resolution.

PET-CT images were analyzed independently by two nuclear physicians with more than 5 years of experience in PET-CT imaging (A.B. and M.S.). All the FDG avid foci were qualitatively evaluated, and maximum standardized uptake value (SUVR) was measured. We recorded the SUVR value of the most FDG-avid lung abnormality.

**Statistical analysis**

Continuous data are expressed as mean ± standard deviation and categorical data as percentage. Descriptive statistics were calculated with Excel software (Microsoft Office 2016).

**RESULTS**

The final population study included 10 patients (5 females; mean age 67 years, range 50-81), of whom 6 were subsequently confirmed positive for SARS-CoV-2 infection: 4 with molecular swab and 2 with quantitative serological test. The remaining 4 cases, although untested, had CT findings strongly consistent with COVID-19-related interstitial pneumonia.

In terms of distribution of lung involvement on CT, in most cases lung abnormalities were multiple and bilateral: 5 patients had involvement of all the pulmonary lobes and 4 patients had 2-4 affected lobes. One patient had a single affected lobe.

The FDG uptake intensity was extremely variable in our population (Table 2). SUnax in patients with 2-4 affected lobes ranged from 2.7 to 11, with a mean value of 6.8. In patients with 5 affected lobes SUnax ranged from 1.5 to 6, with a mean value of 3.8. The patient with 1 involved lobe had a SUnax of 9.4. According to mentioned CT stages, we found an overlap in SUnax values. In early stage SUnax ranged from 1.5 to 11, with a mean SUnax of 6.3 (Figure 1); in progressive stage SUnax ranged from 3.3 to 6.8, with a mean SUnax of 5.1 and in the single patient in the peak stage SUnax ranged from 2.4 to 7.7, with a mean SUnax of 5.1 (Figure 2). None of the patients was in the absorption stage.
Table 2. SUV<sub>max</sub> values according to extension, stage and pattern of lung abnormalities as revealed by co-registration CT.* Feng Pan, Tianhe Ye et al. “Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019”. SUV<sub>max</sub>: maximum standardized uptake value; GGO: ground glass opacities.

| Extension (N° lobes involved) | N° of patients (total 10) | SUV<sub>max</sub> (range) | SUV<sub>max</sub> (mean) |
|-----------------------------|--------------------------|---------------------------|-------------------------|
| All the lobes               | 5                        | 1.5 - 6                   | 3.8                     |
| 2-4 lobes                   | 4                        | 2.7 - 11                  | 6.8                     |
| 1 lobe                      | 1                        | 9.4                       | 9.4                     |
| **Stage**                   |                          |                           |                         |
| 1 - early                   | 5                        | 1.5 - 11                  | 6.3                     |
| 2 - progressive             | 4                        | 3.3 - 6.8                 | 5.1                     |
| 3 - peak                    | 1                        | 2.4 - 7.7                 | 5.1                     |
| 4 - absorption              | 0                        | 0                         | 0                       |
| **Pattern**                 |                          |                           |                         |
| GGO                         | 10                       | 1.5 - 11                  | 6.3                     |
| Consolidation               | 0                        | 0                         | 0                       |
| Mixed (GGO + consolidation) | 3                        | 2.8 - 7.7                 | 5.2                     |

All the patients were asymptomatic for any potential lung involvement at the time of PET-CT, except for one patient who had a single episode of mild fever (37.5°C) the day before the exam. Due to the emergency situation and the lack of symptoms, the patients were discharged and entrusted to the family doctor, in quarantine. During follow-up, none of the patients developed symptoms nor required hospitalization. Two patients (one tested positive for SARS-CoV2 with molecular swab), underwent CECT 30 days after the first PET-CT, showing an improvement of lung involvement.
Discussion

In line with the increasing pandemic emergency during the first COVID-19 outbreak, nuclear medicine imaging workflow at our Institution had been reduced but not completely interrupted. This was aimed to guarantee oncologic monitoring as largely as possible, leading consequently to the occasional incidental detection of pulmonary findings consistent with interstitial pneumonia during routine follow up $^{18}$F-FDG PET-CT scans in oncologic patients.

Considering the concomitant epidemiological setting and the related CT pattern, lung findings were highly suspicious at first sight and suggestive of COVID-19 related pneumonia. A 60% of these cases were then confirmed positive with molecular or serological test. Notably, all the patients were completely asymptomatic for lung involvement at the time of the examination and none of them developed pulmonary symptoms or symptoms requiring hospitalization during follow-up.

Many studies showed that asymptomatic infected individuals can be a contagious source of SARS-CoV-2. Moreover, a significative percentage of these patients could rapidly progress to symptomatic disease (3, 12). Therefore, it is important for epidemiologic and clinical issues to identify, isolate and monitor also asymptomatic cases. According to several studies, the percentage of asymptomatic COVID-19 patients is deeply variable depending on the examined population. Generally, asymptomatic cases seem to account for about 40-45% of total cases of infections and may be associated with subclinical lung abnormalities detected by CT (13, 14). As reported by Varble N. et al, 65% of initially asymptomatic patients presented lung infiltrates at CT scans and the most common pattern was GGO (94%) followed by consolidations (46%). Only half of these asymptomatic patients with pulmonary disease would develop symptoms 1 to 5 days after initial CT scan (15). Accordingly, in our population we depicted GGO in all the included cases. In 50% of the cases GGO were the only lung abnormality, corresponding to the early stage of illness. In 30% of the cases consolidations were also noticed, implying a progressive or peak stage. Therefore, all our patients were in the initial phases of the disease. These results are similar to previously published findings of the recent Italian multicenter study of Albano et al (16).

FDG uptake is generally noted in several inflammatory and infective conditions of the lungs, with a large variability. This is due to the high glycolytic activity of cells involved in the inflammatory process. An increased uptake has been demonstrated also in cases of SARS-CoV-2 infection. It has been already demonstrated that SARS-CoV-2 causes inflammation by different mechanisms, involving macrophages, cytokines and T-cells. Specifically, SARS-CoV-2 enter cells binding the angiotensin-converting enzyme 2 (ACE2), part of the renin-angiotensin system (RAS), highly expressed on the apical side of lung epithelial cells in the alveolar space. By downregulating the RAS system and by other mechanisms, SARS-CoV-2 causes the inflammatory response (17). Being aware of the limited number of cases available, we found high variability in $SUV_{max}$ values regardless the stage of disease, the type of CT patterns and the number of pulmonary involved lobes. Of note, we found higher $SUV_{max}$ values in GGO pattern compared to consolidations. Our results are partially in contrast with the ones of Thornton et al., who found higher $SUV_{max}$ values in more advanced stages of the disease characterized by lung consolidations (18). This may be explained by a lower prevalence of advanced stages with consolidations in our population. However, this variability implies a poor reliability of PET-CT in staging and monitoring the COVID-19 disease.

Our findings are similar to the results reported in other previous studies: Qin et al [4] described 4 presumed cases with COVID-19 pneumonia. In all the patients at least two lobes showed FDG avidity of the GGOs, with $SUV_{max}$ values ranging from 4.6 to 12.2. Differently from our population, in this study all the patients were symptomatic for fever or respiratory symptoms. Setti et al (6) reported a case series of 5 oncologic patients with pulmonary involvement of 2 or more lobes unrelated to cancer metastases. They found consolidation or GGOs with a wide range of FDG uptake (4.3-11.3). In this case series SARS-CoV-2 test has not been performed. GGO have many differential diagnosis (19), including first of all other bacterial and viral pneumonias, but also the interstitial lung diseases, pulmonary edema, ARDS and alveolar hemorrhage. The distribution of GGO, the medical history, patients’ symptoms and laboratory profile can settle the differential diagnosis. The most relevant differential diagnosis is certainly the adenocarcinoma that might present as GGO, either unifocal or multifocal. The recent advent of SARS-CoV-2 infection has added another potential issue in the differentiation of GGO. As a general rule, a lesion that disappears after medical treatment has a high probability to be a benign lesion, while a lesion growing over time suggests a malignant nature. According to literature, a GGO is more probable to be suggestive of a neoplastic condition when a solid component is present.

Some studies have shown that the employment of PET-CT to distinguish between benign and
malignant GGO nodules is inappropriate, especially in the case of pure GGO nodules (20). A short period of follow-up and an empiric therapy, eventually followed by lung biopsy, are considered the optimal method to distinguish between benign and malignant GGO lesions (21, 22). As proof of the inflammatory nature of lung disease in these patients we found a rapid evolution of the lung alterations over time: in two cases an improvement at imaging was observed after 1 months; in two other patients who underwent CECT about 7-10 days before PET scans, one (performed for a clinical trial) was completely negative; the other (performed for high D-dimer rates) showed initial GGO evolving in more compact consolidations in the subsequent PET-CT. In the current epidemiological context, with a high prevalence, GGO are more likely to be COVID-19-related, even when mixed to consolidations and a confirmation with a molecular test remains mandatory in doubtful cases (20). Otherwise, more studies will be required to assess any potential role of nuclear medicine, beside CT findings and the clinical profile of the patient, in the differentiation of GGO related to SARS-CoV-2 among other causes.

This retrospective study has some limitations. The first one is the small sample size, which limits the ability to apply a definite statistical evaluation and our findings to suggestions; however, as aforementioned, oncologic PET scanning in our Institution were significantly reduced by the severity of pandemic peak in the study period. Another limit is the lack of the molecular or serological confirmation in some of the cases, but the lung findings were similar and suggestive even in non-tested patients.

A possible perspective of these findings might be to compare in a high series of patients $SUV_{\text{max}}$ values of SARS-CoV-2 related lung foci with other causes of pulmonary infections.

CONCLUSIONS

$^{18}$F-FDG PET-CT in suspected COVID-19 pulmonary involvement of asymptomatic oncologic patients showed an increase in FDG uptake of GGO and consolidations, but with wide and overlapped range of $SUV_{\text{max}}$ values.

Therefore, CT remains the mainstay for the assessment of lung involvement by SARS-CoV-2 infection, even in asymptomatic patients, recognized as potential source of infection spread.

Ethics approval and consent to participate

Institutional Review Board approval was obtained.

Availability of data and materials

The datasets generated and analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

References

1. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020; 94:154-155.
2. Inui S, Fujikawa A, Jitsu M, et al. Chest CT Findings in Cases from the Cruise Ship “Diamond Princess” with Coronavirus Disease 2019 (COVID-19). Radiol Cardiotorac Imaging. 2020; 2(2): e200110.
3. Kronbichler A, Kresse D, Yoon S, Lee KH, Effenberger M, Shin JI. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. Int J Infect Dis. 2020; 98:180-186.
4. Qin Ch, Liu F, Yen TC, Lan X. $^{18}$F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases. Eur J Nucl Med Mol Imaging. 2020; 47(5):1281-1286.
5. Annunziata S, Bolton R C D, Kamani ChH, Prior J0, Albano D, Bertagna F et al. Role of $^{2-18}$FDG as a Radiopharmaceutical for PET/CT in Patients with COVID-19: A Systematic Review. Pharmaceuticals (Basel). 2020; 13(11):377.
6. Setti L, Kirienko M, Dalto SC, Bonacina M, Bombardieri E. FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients. Eur J Nucl Med Mol Imaging. 2020; 47(7):1649-1656.
7. Lütje S, Marinova M, Kütting D, Attenberger U, Essler M, Bundschuh RA. Nuclear medicine in SARS-CoV-2 pandemia: $^{18}$F-FDG-PET/CT to visualize COVID-19.Nuklearmedizin. 2020; 59(03):276-80.
8. Chuang HH, Emery DJ, Campbell RM, Lu Y. FDG PET/CT in diagnosing COVID-19 infection in a cancer patient with exposure history but minimal symptoms. Clin Nucl Med. 2020; 45(8):656-658.
9. Kwee TC, Kwee RM. Chest CT in COVID-19: what the radiologist needs to know. Radiographics. 2020; 40(7):1848-65.
10. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. European.
journal of nuclear medicine and molecular imaging. 2015; 42(2):328-54.
11. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology. 2020; 295(3):715-21.
12. Vafea MT, Atalla E, Kalligeros M, Mylona E, Shehadeh F, Mylonakis E. Chest CT findings in asymptomatic cases with COVID-19: a systematic review and meta-analysis. Clinical radiology. 2020; 75(11):876.e33–e39.
13. Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Annals of internal medicine. 2020; 173(5):362-7.
14. Al-Sadeq DW, Nasrallah GK. The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review. International Journal of Infectious Diseases. 2020; 98:372-80.
15. Varble N, Blain M, Kassin M, Xu S, Turkbey EB, Amalou A, et al. CT and clinical assessment in asymptomatic and pre-symptomatic patients with early SARS-CoV-2 in outbreak settings. European radiology. 2021; 31(5):3165-76.
16. Albano D, Bertagna F, Aloni P, Baldari S, Baldocci A, Bartolomei M, et al. Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study. European Journal of Nuclear Medicine and Molecular Imaging. 2021; 48: 2871–2882.
17. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clinical immunology. 2020; 215:108427.
18. Thornton A, Fraioli F, Wan S, Garthwaite HS, Ganeshan B, Shortman RI, et al. Evolution of 18F-FDG-PET/CT findings in patients following COVID-19 pneumonia: An Initial Investigation. Journal of Nuclear Medicine. 2021; 62:8.
19. Parekh M, Donuru A, Balasubramanya R, Kapur S. Review of the chest CT differential diagnosis of ground-glass opacities in the COVID era. Radiology. 2020; 297(3):E289-E302.
20. Migliore M, Fornito M, Palazzolo M, Criscione A, Gangemi M, Borrata F, et al. Ground glass opacities management in the lung cancer screening era. Annals of translational medicine. 2018; 6(5).
21. Zhang Y, Fu F, Chen H. Management of ground-glass opacities in the lung cancer spectrum. The Annals of thoracic surgery. 2020; 110(6):1796-804.
22. Zhuo Y, Shan F, Yang S, Zhan Y, Shi Y, Zhang Z. Advances in differential diagnosis of pulmonary ground glass opacity on high resolution computed tomography and histopathology. Radiology of Infectious Diseases. 2020; 7(1):7-11.